Stock Analysis, Dividends, Split History

SSP / Scripps Company financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price16.55
Volume616,300.00
Market Cap ($M)1,158.98
Enterprise Value ($M)1,739.32
Book Value ($M)911.86
Book Value / Share13.02
Price / Book1.27
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding2 69,582,721
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 11,932,722
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.01
Return on Assets (ROA)-0.01
Return on Equity (ROE)-0.02
Balance Sheet (mrq) ($M)
Assets2,089.93
Liabilities1,178.06
Quick Ration/a
Current Ratio2.83
Income Statement (mra) ($M)
Other Sales Revenue Net40,414,000.00
Sales Revenue Net864,834,000.00
Retransmission And Carriage Revenue259,712,000.00
Disposal Group Including Discontinued Operation Revenue0.00
Advertising Revenue564,708,000.00
Operating Income-1.90
Net Income-14.62
Earnings Per Share Diluted-0.16
Earnings Per Share Basic-0.16
Cash Flow Statement (mra) ($M)
Cash From Operations40.85
Cash from Investing-299.07
Cash from Financing-299.07
Identifiers and Descriptors
CUSIP811054402
Central Index Key (CIK)832428
Related CUSIPS
811054952 081105440 811054902

Split History

Stock splits are used by Scripps Company to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Bear of the Day: Meredith Corp. (MDP)

2018-09-18 zacks
Meredith Corporation (MDP - Free Report) is a media and marketing services company based in Des Moines, IA. The company has two operating segments: National Media and Local Media. As of this year, Meredith is the largest magazine company in the world, and some of its biggest brands include People, Sports Illustrated, InStyle, Better Homes & Gardens, Magnolia Journal, Health, Entertainment Weekly, Cooking Light, and Travel + Leisure, among many others. (7-0)

Top Ranked Momentum Stocks to Buy for September 7th

2018-09-07 zacks
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, September 7th:

John Wiley & Sons (JW.A) Stock Crashes on Dismal Q1 Earnings

2018-09-07 zacks
John Wiley & Sons, Inc. (JW.A - Free Report) disappointed investors with first-quarter fiscal 2019 results, wherein the top and the bottom lines crushed their solid surprise record and the latter also deteriorated year over year. Further, the company reiterated its previously issued drab earnings outlook for fiscal 2019. The dismal performance led to an 11% decline in the shares of this leading provider of knowledge and knowledge-related services during yesterday’s trading session.

Top Ranked Momentum Stocks to Buy for September 5th

2018-09-05 investorplace
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, September 5th: (2-0)

Top Ranked Momentum Stocks to Buy for September 5th

2018-09-05 zacks
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, September 5th: (10-1)

CUSIP: 811054402